Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

P3 Health Partners (PIIIW) Shares Outstanding (Weighted Average) (2019 - 2025)

P3 Health Partners' Shares Outstanding (Weighted Average) history spans 7 years, with the latest figure at $3.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 12.57% year-over-year to $3.3 million; the TTM value through Dec 2025 reached $3.3 million, up 12.57%, while the annual FY2025 figure was $3.3 million, 12.57% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $3.3 million in Q4 2025 per PIIIW's latest filing, roughly flat from $3.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $196.6 million in Q4 2021 to a low of $2.4 million in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 5 years is $37.8 million, with a median of $31.5 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 438.94% in 2022, then crashed 96.94% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $196.6 million in 2021, then crashed by 78.85% to $41.6 million in 2022, then skyrocketed by 128.21% to $94.9 million in 2023, then plummeted by 96.94% to $2.9 million in 2024, then increased by 12.57% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for PIIIW's Shares Outstanding (Weighted Average) are $3.3 million (Q4 2025), $3.3 million (Q3 2025), and $3.3 million (Q2 2025).